RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PATIENTS (12-75 YEARS OF AGE) WITH MODERATE TO SEVERE ATOPIC DERMATITIS, WHO ARE INADEQUATELY CONTROLLED BY OR ARE INTOLERANT TO TOPICAL CORTICOSTEROIDS TOPICAL CALCINEURIN INHIBITORS

Trial Profile

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PATIENTS (12-75 YEARS OF AGE) WITH MODERATE TO SEVERE ATOPIC DERMATITIS, WHO ARE INADEQUATELY CONTROLLED BY OR ARE INTOLERANT TO TOPICAL CORTICOSTEROIDS TOPICAL CALCINEURIN INHIBITORS

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2015 Status changed from recruiting to active, no longer recruiting according to United Kingdom Clinical research Network record.
    • 06 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top